| 词条 | Lonza Group |
| 释义 |
| name = Lonza Group AG | logo = Lonza.svg | logo_size = 200px | type = Aktiengesellschaft | traded_as = {{SWX|LONN}}, {{sgx|O6Z}} | foundation = 1897 | location = Basel, Switzerland | key_people = Marc Funk (CEO), Albert Baehny (Chairman) | industry = Chemicals biotechnology | products = Biopharmaceuticals, organic and fine chemicals, chemical synthesis equipment, custom manufacturing of chemicals and related products | revenue = CHF 5.524 million (2018)[1] | operating_income = CHF 842 million (2018)[1] | net_income = | assets = CHF 13.921 billion (end 2018)[1] | equity = CHF 6.290 billion (end 2018)[1] | num_employees = 15,375 {{small|(2018)}} | homepage = [https://web.archive.org/web/20070502084431/http://lonza.com/ www.lonza.com] }}Lonza Group is a Swiss multinational, chemicals and biotechnology company, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including organic, fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis capabilities, detection systems and services for the bioscience sector. HistoryLonza was founded in 1897 in the small Swiss town of Gampel, situated in the canton of Valais, taking its name from the nearby river. Initially the company produced electricity used to manufacture chemicals such as calcium carbide. Lonza moved to neighbouring Visp (where it retains a production site today) in 1909 and began manufacturing synthetic fertilisers, and moves into vitamins, acids, intermediates and additives followed. In 1974, the group merged with aluminium firm Alusuisse, after which the group moved into the biotechnology sector. Lonza de-merged from the Alusuisse-Lonza Group in 1999 and listed on the SWX Swiss Exchange. The company expanded in the United States in 1969 and acquired smaller biopharmaceutical units in recent years. In 1996, Lonza acquired Celltech Biologics and began producing mammalian cell cultures and monoclonal antibodies. In October 2011, Lonza acquired American firm Arch Chemicals for $1.4 billion, as a result becoming the world's largest manufacturer of biocides.[2] On 15 August 2016, the group announced its intention to acquire InterHealth Nutraceuticals,[3] a leader in research, development, manufacture and marketing of value-added nutritional ingredients for use in dietary supplements. The acquisition of the US based company will be done at a value of up to {{US$|300 million}}. In December 2016, the company announced it would acquire Capsugel for {{US$|5.5 billion}}, from private equity firm KKR.[4] Lonza is involved in the manufacturing of biologics with several pharmaceutical companies. Lonza entered into a partnership with Teva in 2009 to develop and manufacture biosimilars. In 2010, they made a deal with GlaxoSmithKline to manufacture therapeutic monoclonal antibodies. In 2014, Lonza entered into an agreement with Bristol-Myers Squibb to manufacture two biologic drugs. Lonza also manufactures Imbruvica for Pharmacyclics and Mydicar for Celladon. In 2015, Lonza contracted with Alexion to construct a new facility dedicated to Alexion manufacturing. In 2017, Lonza and Sanofi partnered to construct a new facility for production of biologics.[5] Corporate structure{{As of|2019}}, Lonza's chief executive officer (CEO) is Marc Funk,[9][10] while the CEO during 2010–2013 was Stefan Borgas.[11]Business operations{{As of|2018}}, Lonza had a twenty-four self-described major sites located in the United States, India, the Czech Republic, Belgium, Spain, China, France, South Africa, Switzerland, Singapore, Mexico, Japan, Brazil and the United Kingdom.[6] This site accounting shows significant changes from a 2016 self-description, which listed sixteen major sites.[7] The presence in India was established in Genome Valley, where ground was broken in 2011.[8][9][10]In 2018, Lonza opened a {{Convert|300,000|sqft|m2}} facility in the United States in Pearland, Texas (a suburb of Houston).[11] This is one of four sites which are focused on cell and gene therapy, the other three being in Portsmouth, New Hampshire; Geleen, Netherlands; and Singapore.[11] {{As of|2016}}, the company employed around 10,000 people,[19]{{Rp|22}} across about 18 countries.[12]{{Rp|89}} {{As of|2018|alt=By 2018,}} employment was noted as 14,500 across 100 sites.[11]References1. ^1 2 3 {{cite web |url=https://annualreport.lonza.com/2018/servicepages/downloads/files/entire_lonza_ar18.pdf |format=PDF |title=Annual Results 2018 }} 2. ^{{cite news|last=Simonian|first=Haig|title=Lonza in $1.4bn acquisition of Arch Chemicals|url=http://www.ft.com/cms/s/0/87235890-ab98-11e0-8a64-00144feabdc0.html#axzz1dakMfQnQ|accessdate=13 November 2011|newspaper=Financial Times|date=11 July 2011}} 3. ^{{Cite press release|title=Lonza Extends Its Reach in the Healthcare Continuum with Acquisition of InterHealth Nutraceuticals|date=15 August 2016|publisher=Lonza|url=https://www.lonza.com/about-lonza/media-center/news/Tensid/2016-08-15-05-00-English.aspx|access-date=2018-04-15}}{{Self-published source|date=September 2018}} 4. ^{{Cite news|url=https://www.genengnews.com/gen-news-highlights/lonza-buys-capsugel-for-55b-cash/81253556|title=Lonza Buys Capsugel for $5.5B Cash|last=|first=|date=15 December 2016|work=Genetic Engineering & Biotechnology News|access-date=2018-04-15|archive-url=|archive-date=|dead-url=}} 5. ^{{Cite web|url=https://www.lonza.com/about-lonza/company-profile/company-history.aspx|title=Company History|last=|first=|date=|website=Company Profile|archive-url=|archive-date=|dead-url=|access-date=2018-04-15}}{{Self-published source|date=September 2018}} 6. ^1 {{Cite web|url=https://www.lonza.com/about-lonza/company-profile/facts-and-figures/facts.aspx|title=Fact Sheet|last=|first=|date=|website=Company Profile|publisher=Lonza|archive-url=|archive-date=|dead-url=|access-date=2018-04-15}}{{Self-published source|date=September 2018}} 7. ^{{Cite web|url=https://www.lonza.com/about-lonza/company-profile/facts-and-figures/facts.aspx|title=Facts|last=|first=|date=|website=Company Profile|publisher=Lonza|archive-url=https://web.archive.org/web/20161010200646/https://www.lonza.com/about-lonza/company-profile/facts-and-figures/facts.aspx|archive-date=10 October 2016|dead-url=|access-date=2018-04-15}}{{Self-published source|date=September 2018}} 8. ^1 {{Cite news|url=http://www.business-standard.com/article/companies/lonza-to-invest-rs-250-cr-in-genome-valley-110092500077_1.html|title=Lonza to invest Rs 250 cr in Genome Valley|last=|first=|date=25 September 2010|work=Business Standard|access-date=2018-04-15|archive-url=|archive-date=|dead-url=|location=India}} 9. ^{{Cite web|url=http://pharma.industry-focus.net/bio-pharmaceuticals/179-lonza-group-to-set-up-a-bio-pharma-unit-at-genome-valley-lonza-group-to-set-up-a-bio-pharma-unit-at-genome-valley.html|title=Lonza Group to set up a bio pharma unit at Genome Valley|last=|first=|date=|website=|publisher=ibis|archive-url=|archive-date=|dead-url=|access-date=2018-04-15}} 10. ^{{Cite press release|title=Lonza provisionally allotted 30 Acres of land in the "Genome Valley", Hyderabad (India)|date=29 May 2009|publisher=Lonza|url=https://www.lonza.com/about-lonza/media-center/news/2009/allotment-30-acres-of-land-in-the-genome-valley.aspx}}{{Self-published source|date=September 2018}} 11. ^1 2 3 {{Cite news|url=https://www.genengnews.com/gen-news-highlights/lonza-opens-cell-and-gene-therapy-facility-in-pearland-tx/81255682/|title=Lonza Opens Cell and Gene Therapy Facility in Pearland, TX|last=Philippidis|first=Alex|date=10 April 2018|work=Genetic Engineering & Biotechnology News|access-date=2018-04-15|archive-url=|archive-date=|dead-url=|department=GEN News Highlights}} 12. ^1 {{Cite web|url=https://www.lonza.com/~/media/Files/Investor%20Relations/Financial%20Reports/2016_Lonza_Annual_Report_Export_v2.ashx?la=en|title=Annual Report 2016|last=|first=|date=|website=Investor Relations|publisher=Lonza|format=PDF|archive-url=|archive-date=|dead-url=|access-date=2018-04-15}}{{Self-published source|date=September 2018}} External links
9 : Chemical companies of Switzerland|Biotechnology companies|Manufacturing companies based in Basel|Manufacturing companies established in 1897|Biotechnology companies of Switzerland|Swiss brands|Multinational companies headquartered in Switzerland|Chemical companies established in 1897|Pharmaceutical companies established in 1897 |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。